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Summary By means of a mathematical score previoulsy generated by discriminant analysis on 90 lung cancer patients, a new and larger
group of 261 subjects [209 with non-small-cell lung cancer (NSCLC) and 52 with small-cell lung cancer (SCLC)] was analysed to confirm the
ability of the method to distinguish between these two types of cancers. The score, which included the serum neuron-specific enolase (NSE)
and CYFRA-21.1 levels, permitted correct classification of 93% of the patients. When the misclassifications were analysed in detail, the most
frequent errors were associated with limited disease SCLC with low NSE levels and with advanced NSCLC with high NSE levels. This
demonstrates the importance of the marker in correctly categorizing patients.
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Many substances in sera have been studied in an attempt to find
potential markers for lung cancer. Unfortunately, none of these
appears to be sensitive and specific enough in terms of a reliable
diagnosis (Gail et al, 1986).
We recently reported an attempt to optimize the use of a combi-
nation of tumour markers, by means of the discriminant analysis
approach, to identify patients with small-cell lung cancer (SCLC)
from those with non-small-cell lung cancer (NSCLC). This
approach permitted generating a score able to correctly classify
95.9% ofpatients with an error rate of 8.3% in SCLC and 2.7% in
NSCLC subjects. The formula to calculate this score was the
following (Paone et al, 1995):
LnNSE x 2.37032 - LnCYFRA-21.1 x 0.37699 - 5.55988
This score may be substituted by another equivalent but simpler
to use:
LnNSE - 0.16 LnCYFRA-21.1 - 2.345.
The encouraging results obtained in the previous investigation
led to the present study with the aim of: (1) verifying whether the
above score showed the same discriminating power in a larger
group of patients; and (2) analysing its reliability in different
subgroups of lung cancer patients.
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MATERIALS AND METHODS
Patients
Sera were obtained from 261 consecutive, unselected patients
affected with histologically proven lung cancer, observed at the
Forlanini Hospital between January 1995 and October 1995. The
population included 209 NSCLC patients (23 stage I, 22 stage II,
51 stage lIla, 38 stage IlIb and 75 stage IV; 151 men and 58
women, median age 64 years, range 39-82 years) and 52 SCLC
patients [32 men and 20 women, median age 64 years, range
37-84 years, 16 with limited disease (LD) and 36 with extended
disease (ED)]. The NSCLCs were classified according to the
WHO classification (World Health Organization, 1982) and
included 71 adenocarcinomas (LADC), one adenosquamous carci-
noma, 130 squamous carcinomas (SQCLC) and seven large-cell
carcinomas (LCLC). Staging was established according to the
literature (IUAC 1988).
Lung cancer diagnosis
Histological diagnosis was made by at least two pathologists,
following World Health Organization criteria (World Health
Organization, 1982). For each patient, three sputum samples
and bronchoscopic biopsies were routinely evaluated. Needle
transthoracic aspiration was needed for 15 patients and resected
tissue for 13.
Tumour markers
Sera were obtained by venepuncture and stored at -20°C until
assayed for the following tumour markers: (1) CEA (carcinoem-
bryonic antigen, produced by Sorin Biomedica, Saluggia, Italy;
normal values less than 5.5 ng ml-'); (2) TPA (tissue polypeptide
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Figure 1 Discriminant analysis generated on 209 NSOLC and 52 SOLO
patients by means of LnNSE and LnCYFRA-21.1 Oanonic variable =
LnNSE -0.16 LnCYFRA-21.1 - 2.345. LD, limited disease SOLO; ED,
extended disease SOLO; NSOLO, Non-small-cell lung cancer; SOLO,
small-cell lung cancer
antigen, produced by Byk Sangtec, Cormano, Italy; normal values
less than 95 U ml-'); (3) CYFRA-21.1 (a cytokeratin antigen, by
CIS Diagnostici, Vercelli, Italy; normal values less than 3.3 ng
ml-'); and (4) NSE (neuron-specific enolase, by CIS Diagnostici;
normal values less than 12.5 ng ml-'). All the tests (radioim-
munoassays) were performed in duplicate, following the manufac-
turers' instructions.
Haemolysed samples were not used because they have been
shown to be a cause of serum NSE increase (Cooper et al, 1985).
Statistical analysis
Non-parametric tests were performed for the individual markers,
because of their non-normal distributions. The Mann-Whitney
rank-sum test or the Kruskal-Wallis one-way variance analysis
was used to compare the different groups. The %2 for trend was
used to evaluate the relationship between stages and errors in the
NSCLC group (stages I, II, IIIa + TIIb and IV).
Discriminant analysis
This method, performed after logarithmic transformation, is a
statistical procedure involving a linear combination of the inde-
pendent variables that discriminates between the a priori defined
groups, thus minimizing the misclassification rates. The classifica-
tion function, named canonic variable, is a score generated by the
program: the canonic variable is a score calculated by adding
together the levels of the variables selected, multiplied by the
appropriate coefficients (negative or positive). The variable is
standardized by means of a constant number, equal to zero (=0)
when the patient cannot be classified into one of the two groups.
In this study, to show the distribution of the patients in each
group and stage, results were examined in terms of the canonic
variable scores ofeach subject.
RESULTS
The results obtained by calculating the canonic variable (negative
canonic variable = NSCLC, and positive canonic variable =
Table 1 Analysis of the errors: no influence of sex and age
Sex Age
(M/F) Median Range
SCLC
Misclassified 6/oa 63b 48-72
Correct 37/9a 65b 37_94
NSCLC
Misclassified 11/ic 55d 45-76
Correct 176/21c 64d 39-82
ap = 0.57 (Fisher's exact test). bp= 0.47 (Mann-Whitney test). cp = 1
(Fisher's exact test). dp= 0.09 (Mann-Whitney test).
SCLC) showed an overall classification rate of 93.1% [18 errors
among 261 subjects: 12 NSCLCs (5.7%) and 6 SCLCs (11.5%);
see Figure 1]. By analysing the different stages, we observed in
NSCLCs a4.3% errorrate (1/23) in stage 1,4.5% (1/22) in stage II,
2.0% (1/51) in stage lIla, 5.3% (2/38) in stage IIIb and, finally,
9.3% (7/75) in stage IV (no significant differences oferror distrib-
ution in the various stages, P=0.26), and in SCLCs an 18.8% rate
(3/13) in the LD stage vs an 8.3% rate (3/36) of misclassifications
among patients in the ED stage (no significant difference,P=0.36).
Figure 1 shows that there is a wide variation of the distribution
of SCLCs as opposed to that of NSCLC patients. This can be
explained by the fact that NSE is the most important discrimi-
nating variable, mainly increased only in SCLC subjects.
No association was observed in terms of the age, sex and error
rates in the two groups (Table 1).
We also analysed the influence of the NSE and CYFRA-21.1
values on the errorrates to evaluate their importance from a classi-
ficatory point of view. As expected, a strong difference was
observed comparing the median NSE values of misclassified and
correctly classified patients. In fact, the median NSE level of the
12 misclassified NSCLC patients was 20.25 ng ml' (range
10.4-69) vs 7.2 ng ml (range 4-16.3) found in the correctly clas-
sified subjects (P<0.00001). A similar, opposite significant differ-
ence was found in SCLC patients: the median serum NSE value
obtained in the six misclassified patients was 8.9 ng ml-'
(5.6-10.6) vs 33.1 ng ml '(11.9-200) of the correctly classified
subjects (P=0.00008).
DISCUSSION
A large data set confirms the efficiency of the previously gener-
ated score. In fact, Figure 1 shows that SCLC can be differentiated
from NSCLC by using a multivariate discriminant analysis on
serum tumour markers (NSE and CYFRA-21.1); NSE being the
most powerful discriminant factor.
Since one of the main limits of the clinical applicability of the
serum tumour markers is its lack of sensitivity in the early stages
(McIntire 1982; Ferrigno et al, 1994), we investigated whetherany
association could be observed between the rate of correct classifi-
cation obtained by the score and the tumour stages. This analysis
showed that stages, sex and age did not influence the error rate.
However, there were a number of misclassified patients affected
with SCLC-LD (with low NSE serum levels), and with advanced
NSCLC, strictly depending on the high NSE levels. This finding
highlights the need to analyse further the differentiation grade of
misclassified cases and a new study ofthis question is planned.
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These findings indicate that NSE is the most important discrim-
inant variable not only for a correct classification but also for
determining errors. The increased number of errors in SCLC-LD
patients is not surprising, as it is known that NSE is stage depen-
dent in this type of cancer (Camey et al, 1982; Cooper 1994). An
association between NSCLC and high NSE levels has been
reported in a subgroup of patients (up to 30%), namely those
showing an enhanced drug sensitivity and a more aggressive clin-
ical tumour behaviour (Zandwjik et al, 1992; Diez et al, 1993).
Currently, the most widely accepted method in the clinical use
of one or more tumour markers is based on the assessment oftheir
cut-off values, placing subjects into groups by means of results
that are above or below certain values. However, this does not use
information available in the quantitative data. This can be amelio-
rated by using the discriminant analysis, which represents one of
the best methods of combining the discriminant power of more
variables to obtain the most accurate classification between two or
more groups (Ameglio et al, 1991, 1994).
The reliability ofthis approach is based on two considerations:
1 In two subsequent studies (the first one already published and
the present report) only NSE and CYFRA-21.1 were selected
as useful discriminating variables. The other marker combina-
tions did not produce acceptable classification rates (results
not shown).
2 Recent studies indicate that NSE and CYFRA-21.1 are the
most useful tumour markers for SCLC and NSCLC classifica-
tion (Burghuber et al, 1990; Wieskopfet al, 1995) and, there-
fore, it is not surprising that the discriminant analysis
combined these two markers together.
Given the confirmed reliability ofour approach, a possible clin-
ical target of the score described could be represented by those
patients in whom lung cancer is diagnosed by means of clinical
and radiological signs, but where the histological type cannot be
recognized because cytology is negative and invasive diagnostic
techniques cannot be applied, especially in elderly patients with
poor cardiorespiratory functions.
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